BARCELONA, SPAIN and SHANGHAI, CHINA (January 14, 2011) — Laboratorios SALVAT, S.A. (SALVAT) announced today that it has engaged Luqa Ventures, Co. Ltd. (LUQA) to market its EBERNET® product in the China and other asian markets via an exclusive license agreement. More details to come soon.
EBERCONAZOLE is a new chemical entity with antifungal activity developed by SALVAT that has showed improved efficacy compared to Clotrimazole and Miconazole in Phase III Clinical Trials.
Laboratorios SALVAT, S.A.
Based in Barcelona, Spain, SALVAT is a privately owned pharmaceutical group closely identified with technological innovation and strongly committed to R&D. Founded in 1955, SALVAT has a presence in over 30 countries worldwide in collaboration with well reputed pharmaceutical partners. SALVAT is working to strengthen its international presence by licensing its own developments and by emphasizing collaborations regarding its pipeline products. More information regarding SALVAT can be found at www.salvatbiotech.com
Luqa Ventures, Co. Ltd.
Based in Hong Kong, LUQA is a specialty pharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of care for unmet medical needs in emerging markets. The company is committed to creating value by building a best in-class product portfolio and an outstanding team through the nurturing of a unique company culture.